Taxotere
(docetaxel)ApprovedSmall molecule
Docetaxel is a chemotherapy drug used to treat various types of cancer, including breast cancer, lung cancer, prostate cancer, and gastric cancer by slowing or stopping the growth of cancer cells.[2] Taxotere is currently approved and in use across 141 indications[4].[1]
Taxotere is one of 1470 small molecule programs targeting Head and Neck Carcinoma. It is currently in Approved.
141
Indications
1,648
Total Trials
29
Active Trials
1,469
Competitors
11
FDA Applications
NDA/BLA/ANDA regulatory filings
8
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 139 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Taxotere
AAvyxa
Approved
Halaven
EisaiPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Adenocard
AstellasPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer36 trials
Show 33 more trials
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Completed·—·Phase 2·NCT00003953·39 enrolled
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 3·NCT07377643·540 enrolled
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer
Completed·—·Phase 3·NCT00146549·250 enrolled
Prostate Cancer23 trials
Show 20 more trials
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
Completed·—·Phase 2·NCT00321646·42 enrolled
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Terminated·—·Phase 2·NCT03093272·9 enrolled
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Completed·—·Phase 3·NCT00116142·350 enrolled
Non-Small Cell Lung Cancer22 trials
Show 19 more trials
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
Completed·—·Phase 3·NCT00216125·243 enrolled
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
Unknown status·IIstituto Nazionale per lo Studio e la Cura dei Tumori·Phase 3·NCT00022022·200 enrolled
Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer
Terminated·—·Phase 2·NCT02157116·13 enrolled
Lung Cancer6 trials
Metastatic Prostate Cancer5 trials
Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Completed·—·Phase 2·NCT00276549·35 enrolled
Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
Completed·—·Phase 2·NCT00005857
73 more indications
Gastric Cancer5 trials
Head and Neck Squamous Cell Carcinoma5 trials
Small Cell Lung Cancer4 trials
Advanced Solid Tumors4 trials
Nasopharyngeal Carcinoma3 trials
Advanced Cancer3 trials
Induction Chemotherapy3 trials
Squamous Cell Carcinoma3 trials
Patients With Advanced Solid Tumors2 trials
Head and Neck Cancer2 trials
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Completed·—·Phase 1·NCT01783587·29 enrolled
Esophageal Cancer2 trials
Gastroesophageal Junction2 trials
Locally Advanced2 trials
Adenocarcinoma2 trials
Metastatic Urothelial Cancer2 trials
Fallopian Tube Cancer2 trials
Metastatic Head and Neck Cancer2 trials
Head Neck Cancer2 trials
Cancer2 trials
Ovarian Cancer2 trials
Metastatic2 trials
Cancer of the Prostate1 trial
Toripalimab1 trial
Newly Diagnosed1 trial
Advanced Urothelial Cancer1 trial
Chemotherapy1 trial
Growth1 trial
Toxicity1 trial
Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer
Not yet recruiting·—·Phase 2·NCT06360978·30 enrolled
Advanced or Metastatic Solid Tumors1 trial
Prostatectomy1 trial
Pancreatic Cancer1 trial
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
Completed·—·Phase 2·NCT00137761·32 enrolled
Esophagus Cancer1 trial
First Line Therapy1 trial
Recurrent Head and Neck Cancer1 trial
Fluorouracil1 trial
Overall Survival1 trial
Gastric Carcinoma1 trial
Intraperitoneal Chemotherapy1 trial
Advanced or Metastatic NSCLC1 trial
Esophageal Squamous Cell Carcinoma1 trial
Metastatic Colorectal Cancer1 trial
Oral Squamous Cell Carcinoma1 trial
Chemoradiotherapy1 trial
Primary Peritoneal Cancer1 trial
Second-line Therapy1 trial
Organ Preservation1 trial
Recurrent NSCLC1 trial
Liver Cancer1 trial
Capecitabine1 trial
Metastatic Solid Tumors1 trial
Clinical Trial1 trial
Radiotherapy1 trial
Neuroendocrine Cancer1 trial
Gastroesophageal Junction Cancer1 trial
Chemoradiation1 trial
First-line Treatment1 trial
Cervical Cancer1 trial
Soft Tissue Sarcoma1 trial
Recurrent or Metastatic1 trial
Non-Small Cell Lung Adenocarcinoma1 trial
Uterine Leiomyosarcoma1 trial
Prostate1 trial
Pazopanib, Docetaxel, Prednisone Prostate
Completed·—·Phase 1·NCT01385228·36 enrolled
Advanced NSCLC1 trial
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03611738·21 enrolled
Patients With Solid Tumors1 trial
Tics1 trial
Selected Subjects With Advanced Solid Tumors1 trial
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Active, not recruiting·SSichuan Kelun Pharmaceutical Research Institute Co., Ltd.·Phase 2·NCT05631262·321 enrolled
Effectiveness1 trial
TED1 trial
Oropharyngeal Cancer1 trial
Regulatory
FDA Approval Timeline[5]
Aug 3, 2010
TAXOTERE
NDA NDA020449
Mar 8, 2011
DOCETAXEL
NDA NDA022234
May 3, 2011
DOCEFREZ
NDA NDA022534
Jun 8, 2011
DOCETAXEL
NDA NDA201195
Jun 29, 2011
DOCETAXEL
NDA NDA201525
Jan 11, 2012
DOCETAXEL
NDA NDA022312
Apr 12, 2013
DOCETAXEL
NDA NDA203551
Mar 13, 2014
DOCETAXEL
NDA NDA202356
Dec 22, 2015
DOCETAXEL
NDA NDA205934
Nov 22, 2022
DOCIVYX
NDA NDA215813
Oct 23, 2024
BEIZRAY
NDA NDA218711
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Taxotere drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for docetaxel. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]